Lassen U - Search Results

1

Extracranial metastases in glioblastoma-Two case stories.

Schou Nørøxe D, Regner Michaelsen S, Broholm H, Møller S, Skovgaard Poulsen H, Lassen U. Schou Nørøxe D, et al. Among authors: lassen u. Clin Case Rep. 2018 Dec 27;7(2):289-294. doi: 10.1002/ccr3.1980. eCollection 2019 Feb. Clin Case Rep. 2018. PMID: 30847191 Free PMC article.

2

Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.

Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sørensen M, Kosteljanetz M, Broholm H, Stockhausen MT, Poulsen HS. Hasselbalch B, et al. Among authors: lassen u. Neuro Oncol. 2010 May;12(5):508-16. doi: 10.1093/neuonc/nop063. Epub 2010 Feb 5. Neuro Oncol. 2010. PMID: 20406901 Free PMC article. Clinical Trial.

3

Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan.

Hasselbalch B, Eriksen JG, Broholm H, Christensen IJ, Grunnet K, Horsman MR, Poulsen HS, Stockhausen MT, Lassen U. Hasselbalch B, et al. Among authors: lassen u. APMIS. 2010 Aug;118(8):585-94. doi: 10.1111/j.1600-0463.2010.02631.x. APMIS. 2010. PMID: 20666740

4

A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.

Møller S, Grunnet K, Hansen S, Schultz H, Holmberg M, Sorensen M, Poulsen HS, Lassen U. Møller S, et al. Among authors: lassen u. Acta Oncol. 2012 Jul;51(6):797-804. doi: 10.3109/0284186X.2012.681063. Epub 2012 May 1. Acta Oncol. 2012. PMID: 22548369 Clinical Trial.

5

18F-FET microPET and microMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma.

Nedergaard MK, Michaelsen SR, Urup T, Broholm H, El Ali H, Poulsen HS, Stockhausen MT, Kjaer A, Lassen U. Nedergaard MK, et al. Among authors: lassen u. PLoS One. 2015 Feb 13;10(2):e0115315. doi: 10.1371/journal.pone.0115315. eCollection 2015. PLoS One. 2015. PMID: 25680186 Free PMC article.

6

Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan.

Urup T, Dahlrot RH, Grunnet K, Christensen IJ, Michaelsen SR, Toft A, Larsen VA, Broholm H, Kosteljanetz M, Hansen S, Poulsen HS, Lassen U. Urup T, et al. Among authors: lassen u. Acta Oncol. 2016;55(4):418-22. doi: 10.3109/0284186X.2015.1114679. Epub 2016 Feb 1. Acta Oncol. 2016. PMID: 26828563

7

Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients.

Urup T, Michaelsen SR, Olsen LR, Toft A, Christensen IJ, Grunnet K, Winther O, Broholm H, Kosteljanetz M, Issazadeh-Navikas S, Poulsen HS, Lassen U. Urup T, et al. Among authors: lassen u. Mol Oncol. 2016 Oct;10(8):1160-8. doi: 10.1016/j.molonc.2016.05.005. Epub 2016 May 26. Mol Oncol. 2016. PMID: 27262894 Free PMC article.

8

Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients.

Urup T, Staunstrup LM, Michaelsen SR, Vitting-Seerup K, Bennedbæk M, Toft A, Olsen LR, Jønson L, Issazadeh-Navikas S, Broholm H, Hamerlik P, Poulsen HS, Lassen U. Urup T, et al. Among authors: lassen u. BMC Cancer. 2017 Apr 18;17(1):278. doi: 10.1186/s12885-017-3251-3. BMC Cancer. 2017. PMID: 28420326 Free PMC article.

9

Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival.

Michaelsen SR, Urup T, Olsen LR, Broholm H, Lassen U, Poulsen HS. Michaelsen SR, et al. Among authors: lassen u. J Neurooncol. 2018 May;137(3):533-542. doi: 10.1007/s11060-017-2739-7. Epub 2018 Jan 5. J Neurooncol. 2018. PMID: 29305787

10

Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan.

Toft A, Urup T, Christensen IJ, Michaelsen SR, Lukram B, Grunnet K, Kosteljanetz M, Larsen VA, Lassen U, Broholm H, Poulsen HS. Toft A, et al. Among authors: lassen u. Cancer Invest. 2018 Feb 7;36(2):165-174. doi: 10.1080/07357907.2018.1430818. Epub 2018 Feb 2. Cancer Invest. 2018. PMID: 29393706 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

199 results

Search Page